Diverse origins of the myofibroblast-implications for kidney fibrosis

Nature Reviews Nephrology

Volumn 11, Issue 4, 2015, Pages 233-244

  Falke, Lucas L ^a   Gholizadeh, Shima ^b   Goldschmeding, Roel ^a   Kok, Robbert J ^b   Nguyen, Tri Q ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NANOCARRIER;

AORTA MEDIA; CELL LINEAGE; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FOCAL ADHESION; HUMAN; KIDNEY FIBROSIS; KIDNEY INJURY; MECHANICAL STRESS; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; STEM CELL; TARGET CELL; WOUND HEALING; CLINICAL TRIAL (TOPIC); FIBROSIS; KIDNEY; KIDNEY DISEASES; PATHOLOGY;

CLINICAL TRIALS AS TOPIC; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; MYOFIBROBLASTS;

EID: 84925678297     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.246     Document Type: Review

References (125)

1. Kok H. M., Falke L. L., Goldschmeding R. & Nguyen T. Q. Targeting CTGF EGF and PDGF pathways to prevent progression of kidney disease. Nat. Rev. Nephrol. 10, 700-711 (2014).
2. Hakroush S., et al. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis cyst formation and glomerular disease. Am. J. Pathol. 175, 1883-1895 (2009
3. Thannickal V. J. Aging antagonistic pleiotropy and fibrotic disease. Int. J. Biochem. Cell Biol. 42, 1398-1400 (2010
4. Akhurst R. J. & Hata A. Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790-811 (2012
5. Ryu J. H. & Daniels C. E. Advances in the management of idiopathic pulmonary fibrosis. F1000 Med. Rep. 2, 28 (2010
6. Duffield J. S., Lupher M., Thannickal V. J. & Wynn T. A. Host responses in tissue repair and fibrosis. Annu. Rev. Pathol. 8, 241-276 (2013
7. Novak M. L. & Koh T. J. Macrophage phenotypes during tissue repair. J. Leukoc. Biol. 93, 875-881 (2013
8. Strutz F. & Muller G. A. Mechanisms of renal fibrogenesis. in Immunological Renal Diseases 2nd edn (Eds Neilson E.G. & Couser W.G.) 73-101 (Lippincott-Raven 2001
9. Sica A. & Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787-795 (2012
10. Wynn T. A. & Ramalingam T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18, 1028-1040 (2012
11. Micallef L., et al. The myofibroblast multiple origins for major roles in normal and pathological tissue repair. Fibrogenesis Tissue Repair 5 (Suppl. 1), S5 (2012
12. Meng X. M., Nikolic-Paterson D. J. & Lan H. Y. Inflammatory processes in renal fibrosis. Nat. Rev. Nephrol. 10, 493-503 (2014
13. Tomasek J. J., Gabbiani G., Hinz B., Chaponnier C. & Brown R. A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 3, 349-363 (2002
14. Meran S. & Steadman R. Fibroblasts and myofibroblasts in renal fibrosis. Int. J. Exp. Pathol. 92, 158-167 (2011
15. Boor P. & Floege J. The renal (myo-)fibroblast: a heterogeneous group of cells. Nephrol. Dial. Transplant. 27, 3027-3036 (2012
16. Gabbiani G. & Majno G. Dupuytren's contracture: fibroblast contraction?. An ultrastructural study. Am. J. Pathol. 66, 131-146 (1972
17. Eyden B. The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J. Cell. Mol. Med. 12, 22-37 (2008
18. Duffield J. S. Cellular and molecular mechanisms in kidney fibrosis. J. Clin. Invest. 124, 2299-2306 (2014
19. Hinz B., et al. The myofibroblast: one function multiple origins. Am. J. Pathol. 170, 1807-1816 (2007
20. Lin S. L., Kisseleva T., Brenner D. A. & Duffield J. S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173, 1617-1627 (2008
21. Hinz B. The myofibroblast: paradigm for a mechanically active cell. J. Biomech. 43, 146-155 (2010
22. Strutz F., et al. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 130, 393-405 (1995
23. Leader M., Collins M., Patel J. & Henry K. Vimentin: an evaluation of its role as a tumour marker. Histopathology 11, 63-72 (1987
24. Osterreicher C. H., et al. Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc. Natl Acad. Sci. USA 108, 308-313 (2011
25. Mor-Vaknin N., Punturieri A., Sitwala K. & Markovitz D. M. Vimentin is secreted by activated macrophages. Nat. Cell Biol. 5, 59-63 (2003
26. Lewandoski M. Conditional control of gene expression in the mouse. Nat. Rev. Genet. 2, 743-755 (2001
27. Dressler G. R. Advances in early kidney specification development and patterning. Development 136, 3863-3874 (2009
28. Asada N., et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J. Clin. Invest. 121, 3981-3990 (2011
29. Humphreys B. D., et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85-97 (2010
30. Zeisberg E. M., Potenta S. E., Sugimoto H., Zeisberg M. & Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial to mesenchymal transition. J. Am. Soc. Nephrol. 19, 2282-2287 (2008
31. Sauer B. Inducible gene targeting in mice using the Cre/lox system. Methods 14, 381-392 (1998
32. Picard N., Baum O., Vogetseder A., Kaissling B. & Le Hir M. Origin of renal myofibroblasts in the model of unilateral ureter obstruction in the rat. Histochem. Cell Biol. 130, 141-155 (2008
33. Faulkner J. L., Szcykalski L. M., Springer F. & Barnes J. L. Origin of interstitial fibroblasts in an accelerated model of angiotensin II-induced renal fibrosis. Am. J. Pathol. 167, 1193-1205 (2005
34. Lebleu V. S., et al. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047-1053 (2013
35. Khairoun M., et al. Renal ischemia-reperfusion induces a dysbalance of angiopoietins accompanied by proliferation of pericytes and fibrosis. Am. J. Physiol. Renal Physiol. 305, F901-F910 (2013
36. Kida Y. & Duffield J. S. Pivotal role of pericytes in kidney fibrosis. Clin. Exp. Pharmacol. Physiol. 38, 467-473 (2011
37. Schlondorff D. The glomerular mesangial cell: an expanding role for a specialized pericyte. FASEB J. 1, 272-281 (1987
38. Sam R., et al. Glomerular epithelial cells transform to myofibroblasts: early but not late removal of TGF-β1 reverses transformation. Transl. Res. 148, 142-148 (2006
39. Whiteside C., et al. Regulation of mesangial cell alpha-smooth muscle actin expression in 3-dimensional matrix by high glucose and growth factors. Nephron Exp. Nephrol. 109, e46-e56 (2008
40. Alpers C. E., Hudkins K. L., Gown A. M. & Johnson R. J. Enhanced expression of muscle-specific actin in glomerulonephritis. Kidney Int. 41, 1134-1142 (1992
41. Matsubara T., et al. Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy. Lab. Invest. 86, 357-368 (2006
42. Lamouille S., Xu, J. & Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178-196 (2014
43. Kalluri R. & Weinberg R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428 (2009
44. Ng, Y. Y., et al. Glomerular epithelial-myofibroblast transdifferentiation in the evolution of glomerular crescent formation. Nephrol. Dial. Transplant. 14, 2860-2872 (1999
45. Ng, Y. Y., et al. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int. 54, 864-876 (1998
46. Yamaguchi Y., et al. Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am. J. Kidney Dis. 54, 653-664 (2009
47. Bariety J., et al. Glomerular epithelial-mesenchymal transdifferentiation in pauci-immune crescentic glomerulonephritis. Nephrol. Dial. Transplant. 18, 1777-1784 (2003
48. Rastaldi M. P., et al. Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int. 62, 137-146 (2002
49. Vongwiwatana A., Tasanarong A., Rayner D. C., Melk A. & Halloran P. F. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am. J. Transplant. 5, 1367-1374 (2005
50. Chen C. L., et al. Erythropoietin suppresses epithelial to mesenchymal transition and intercepts Smad signal transduction through a MEK-dependent mechanism in pig kidney (LLC-PK1) cell lines. Exp. Cell Res. 316, 1109-1118 (2010
51. Tasanarong A., Kongkham S. & Khositseth S. Dual inhibiting senescence and epithelial to mesenchymal transition by erythropoietin preserve tubular epithelial cell regeneration and ameliorate renal fibrosis in unilateral ureteral obstruction. Biomed. Res. Int. 2013, 308130 (2013
52. Yang J. & Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J. Am. Soc. Nephrol. 13, 96-107 (2002
53. Zeisberg M., et al. BMP-7 counteracts TGF beta1 induced epithelial to mesenchymal transition and reverses chronic renal injury. Nat. Med. 9, 964-968 (2003
54. Iwano M., et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110, 341-350 (2002
55. Li, L., Zepeda-Orozco D., Black R. & Lin F. Autophagy is a component of epithelial cell fate in obstructive uropathy. Am. J. Pathol. 176, 1767-1778 (2010
56. Koesters R., et al. Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am. J. Pathol. 177, 632-643 (2010
57. Thiery J. P., Acloque H., Huang R. Y. & Nieto M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009
58. Galichon P., Finianos S. & Hertig A. EMT-MET in renal disease: should we curb our enthusiasm?. Cancer Lett. 341, 24-29 (2013
59. Kriz W., Kaissling B. & Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy?. J. Clin. Invest. 121, 468-474 (2011
60. Smeets B., et al. Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J. Am. Soc. Nephrol. 20, 2604-2615 (2009
61. Hackl M. J., et al. Tracking the fate of glomerular epithelial cells in vivo using serial multiphoton imaging in new mouse models with fluorescent lineage tags. Nat. Med. 19, 1661-1666 (2013
62. Schulte K., et al. Origin of parietal podocytes in atubular glomeruli mapped by lineage tracing. J. Am. Soc. Nephrol. 25, 129-141 (2014
63. Burford J. L., et al. Intravital imaging of podocyte calcium in glomerular injury and disease. J. Clin. Invest. 124, 2050-2058 (2014
64. Eremina V., et al. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J. Am. Soc. Nephrol. 17, 724-735 (2006
65. Sakamaki Y., et al. Injured kidney cells express SM22α (transgelin): Unique features distinct from alpha-smooth muscle actin (αSMA). Nephrology (Carlton) 16, 211-218 (2011
66. Piera-Velazquez S., Li, Z. & Jimenez S. A. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am. J. Pathol. 179, 1074-1080 (2011
67. Li, J., Qu, X. & Bertram J. F. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am. J. Pathol. 175, 1380-1388 (2009
68. Phua Y. L., Martel N., Pennisi D. J., Little M. H. & Wilkinson L. Distinct sites of renal fibrosis in Crim1 mutant mice arise from multiple cellular origins. J. Pathol. 229, 685-696 (2013
69. Curci C., et al. Endothelial to mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. Nephrol. Dial. Transplant. 29, 799-808 (2014
70. Bellini A. & Mattoli S. The role of the fibrocyte a bone marrow-derived mesenchymal progenitor in reactive and reparative fibroses. Lab. Invest. 87, 858-870 (2007
71. Lee C. H., Shah B., Moioli E. K. & Mao J. J. CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. J. Clin. Invest. 120, 3340-3349 (2010
72. Yang L., et al. Bone marrow-derived mesenchymal stem cells differentiate to hepatic myofibroblasts by transforming growth factor-beta1 via sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis. Am. J. Pathol. 181, 85-97 (2012
73. Reich B., et al. Fibrocytes develop outside the kidney but contribute to renal fibrosis in a mouse model. Kidney Int. 84, 78-89 (2013
74. Broekema M., et al. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J. Am. Soc. Nephrol. 18, 165-175 (2007
75. Grimm P. C., et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N. Engl. J. Med. 345, 93-97 (2001
76. Rienstra H., et al. Donor and recipient origin of mesenchymal and endothelial cells in chronic renal allograft remodeling. Am. J. Transplant. 9, 463-472 (2009
77. Roufosse C., et al. Bone marrow-derived cells do not contribute significantly to collagen I synthesis in a murine model of renal fibrosis. J. Am. Soc. Nephrol. 17, 775-782 (2006
78. Lin S. L., Castano A. P., Nowlin B. T., Lupher M. L. Jr & Duffield J. S. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J. Immunol. 183, 6733-6743 (2009
79. Eddy A. A., Lopez-Guisa J. M., Okamura D. M. & Yamaguchi I. Investigating mechanisms of chronic kidney disease in mouse models. Pediatr. Nephrol. 27, 1233-1247 (2012
80. De Palma M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005
81. Chang L., et al. Differentiation of vascular smooth muscle cells from local precursors during embryonic and adult arteriogenesis requires Notch signaling. Proc. Natl Acad. Sci. USA 109, 6993-6998 (2012
82. Eddy A. A. The origin of scar-forming kidney myofibroblasts. Nat. Med. 19, 964-966 (2013
83. Zeisberg M. & Duffield J. S. Resolved: EMT produces fibroblasts in the kidney. J. Am. Soc. Nephrol. 21, 1247-1253 (2010
84. Tampe D. & Zeisberg M. Potential approaches to reverse or repair renal fibrosis. Nat. Rev. Nephrol. 10, 226-237 (2014
85. Distler J. H. & Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann. Rheum. Dis. 69 (Suppl. 1), i48-i51 (2010
86. Prakash J., et al. Novel therapeutic targets for the treatment of tubulointerstitial fibrosis. Current Signal Transduction Therapy 3, 97-111 (2014
87. Bansal R., Prakash J., De Ruiter M. & Poelstra K. Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFbetaR bicyclic peptide inhibits liver fibrogenesis in vivo. PLoS ONEe 9, e89878 (2014
88. Hagens W. I., et al. Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated. Pharm. Res. 24, 566-574 (2007
89. Christensen E. I., Birn H., Storm T., Weyer K. & Nielsen R. Endocytic receptors in the renal proximal tubule. Physiology (Bethesda) 27, 223-236 (2012
90. Prakash J., et al. Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. J. Am. Soc. Nephrol. 19, 2086-2097 (2008
91. Shillingford J. M., Leamon C. P., Vlahov I. R. & Weimbs T. Folate-conjugated rapamycin slows progression of polycystic kidney disease. J. Am. Soc. Nephrol. 23, 1674-1681 (2012
92. Prakash J., et al. Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl) 2 (4-hydroxyphenyl) 5 (4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis. J. Pharmacol. Exp. Ther. 319, 8-19 (2006
93. Lin Y., et al. Targeted drug delivery to renal proximal tubule epithelial cells mediated by 2-glucosamine. J. Control Release 167, 148-156 (2013
94. Wang X., et al. Effects of mycophenolic acid-glucosamine conjugates on the base of kidney targeted drug delivery. Int. J. Pharm. 456, 223-234 (2013
95. Floege J., Eitner F. & Alpers C. E. A new look at platelet-derived growth factor in renal disease. J. Am. Soc. Nephrol. 19, 12-23 (2008
96. Greupink R., et al. Mannose 6 phosphate/insulin-Like growth factor-II receptors may represent a target for the selective delivery of mycophenolic acid to fibrogenic cells. Pharm. Res. 23, 1827-1834 (2006
97. Moreno M., et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 51, 942-952 (2010
98. Van Beuge M. M., et al. Enhanced effectivity of an ALK5-inhibitor after cell-specific delivery to hepatic stellate cells in mice with liver injury. PLoS ONE 8, e56442 (2013
99. Dolman M. E., Harmsen S., Storm G., Hennink W. E. & Kok R. J. Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells. Adv. Drug Deliv. Rev. 62, 1344-1357 (2010
100. Leeuwis J. W., Nguyen T. Q., Dendooven A., Kok R. J. & Goldschmeding R. Targeting podocyte-associated diseases. Adv. Drug Deliv. Rev. 62, 1325-1336 (2010
101. Scindia Y. M., Deshmukh U. S. & Bagavant H. Mesangial pathology in glomerular disease: targets for therapeutic intervention. Adv. Drug Deliv. Rev. 62, 1337-1343 (2010
102. Qin W., et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 22, 1462-1474 (2011
103. Trachtman H., et al. A phase 1, single-dose study of fresolimumab an anti TGF beta antibody in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236-1243 (2011
104. A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis(FSGS). ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01665391?term=fresolimumab&rank=3 (2014
105. Adler S. G., et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin. J. Am. Soc. Nephrol. 5, 1420-1428 (2010
106. Richeldi L., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2071-2082 (2014
107. Liu N., et al. Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J. Am. Soc. Nephrol. 23, 854-867 (2012
108. Elmholdt T. R., Buus N. H., Ramsing M. & Olesen A. B. Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized uncontrolled clinical trial. J. Eur. Acad. Dermatol. Venereol. 27, 779-784 (2013
109. Illouz F., Braun D., Briet C., Schweizer U. & Rodien P. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur. J. Endocrinol. 171, R91-R99 (2014
110. Hartmann J. T., Haap M., Kopp H. G. & Lipp H. P. Tyrosine kinase inhibitors-a review on pharmacology metabolism and side effects. Curr. Drug Metab. 10, 470-481 (2009
111. Hong S., et al. Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials. Onco. Targets Ther. 7, 1851-1867 (2014
112. Casanovas O., Hicklin D. J., Bergers G. & Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005
113. Connolly E. C., et al. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TbetaRI/II kinase inhibition with LY2109761. Cancer Res. 71, 2339-2349 (2011
114. Dolman M. E., et al. Imatinib ULS lysozyme: a proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases. J. Control Release 157, 461-468 (2012
115. Prakash J., et al. Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Pharm. Res. 25, 2427-2439 (2008
116. Dankers P. Y., et al. Hierarchical formation of supramolecular transient networks in water: a modular injectable delivery system. Adv. Mater. 24, 2703-2709 (2012
117. Lebleu V. S., Sugimoto H., Miller C. A., Gattone V. H. 2nd & Kalluri R. Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. Lab. Invest. 88, 284-292 (2008
118. Stokman G., et al. Epac-Rap signaling reduces oxidative stress in the tubular epithelium. J. Am. Soc. Nephrol. 25, 1474-1485 (2014
119. Wang X., et al. Mechanistic studies of a novel mycophenolic Acid-glucosamine conjugate that attenuates renal ischemia/reperfusion injury in rat. Mol. Pharm. 11, 3503-3514 (2014
120. Yuan Z. X., et al. Randomly 50% N-acetylated low molecular weight chitosan as a novel renal targeting carrier. J. Drug Target. 15, 269-278 (2007
121. Suzuki K., et al. Specific renal delivery of sugar-modified low molecular weight peptides. J. Pharmacol. Exp. Ther. 288, 888-897 (1999
122. Scindia Y., Deshmukh U., Thimmalapura P. R. & Bagavant H. Anti-alpha8 integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus. Arthritis Rheum. 58, 3884-3891 (2008
123. Suana A. J., et al. Single application of low-dose mycophenolate mofetil OX7 immunoliposomes ameliorates experimental mesangial proliferative glomerulonephritis. J. Pharmacol. Exp. Ther. 337, 411-422 (2011
124. Asgeirsdottir S. A., et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am. J. Physiol. Renal Physiol. 294, F554-F561 (2008
125. Hauser P. V., et al. Novel siRNA delivery system to target podocytes in vivo. PLoS One 5, e9463 (2010